Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab)
BackgroundCemiplimab was licensed in the United Kingdom (UK) in 2019 for the treatment of patients with locally advanced and metastatic CSCC not suitable for curative surgery or radiotherapy (advanced CSCC [aCSCC]). No UK multi-center studies have investigated the real-world experience of cemiplimab...
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Frontiers Media S.A.
2024-07-01
|
| 叢編: | Frontiers in Immunology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1408667/full |